Skip to main content
. Author manuscript; available in PMC: 2011 Jul 13.
Published in final edited form as: Nat Biotechnol. 2010 Feb 14;28(3):249–255. doi: 10.1038/nbt.1606

Figure 3. Effects of meclizine on cellular energy metabolism.

Figure 3

(a) Cell viability of MCH58 fibroblasts cells cultured in glucose or galactose media with varying doses of meclizine for three days. Data are expressed as mean ± SD (n = 5).

(b) OCR in MCH58 fibroblasts cells cultured in glucose media with varying doses of meclizine for 200 min. Data are expressed as mean ± SD (n = 3). (*P<0.05; **P<0.005; two-sided t-test).

(c,d) OCR (c) and ECAR (d) in multiple cell types cultured in glucose media with 50 μM meclizine or DMSO for 200 min. Data are expressed as mean ± SD (n ≥ 3). (* P<0.05; two-sided t-test).

(e) Time course of meclizine (50 μM) mediated OCR reduction over DMSO baseline compared to other inhibitors of OXPHOS (1 μM each) in 293 cells. Data are expressed as mean ± SD (n ≥ 3).

(f) HIF-1α and HIF-2α detection by Western blot analysis of protein extract from HeLa cells after 6 hrs treatment with 0.1 % DMSO, 100 μM deferoxamine (DFO) or 50 μM meclizine. The complete immunoblot is provided as Supplementary Fig. 7b.